Rapamycin’s Role in Aging and IntegraGen’s New EPOC Study as Published on Oncotarget

A new Oncotarget article suggests that gut homeostasis plays a crucial role in the bodies of aging individuals. It also suggests that a mTOR specific inhibitor known as rapamycin has enhanced longevity in diverse evolutionary species. The inhibitor reduces the rate at which proliferation takes place in the intestinal cells. Rapamycin also slows down the expansion of microbes in aging guts. It keeps the stem cells active by inhibiting mTOR. These results are used in explaining how lifespan and healthspan can be extended in Drosophila.

IntegraGen’s New EPOC Study

In a move to avail results of a new clinical trial online, IntegraGen released new publication on the Oncotarget online journal. The company’s top scientists got the results after they analyzed miR-31-3p expression in patients’ tumor samples. The publication also explains the relationship between the efficacy of anti-EGFR treatment and miR-31-3p expression. It also explains the findings of the clinical study known as the NEW EPOC Study.Prof. John Bridgewater, a medical oncologist, partnered with other researchers in authoring the report of this innovative study. Prof. Bridgewater, who was also an investigator in the study, said that his team is honored to continue availing clinical research from the New EPOC Study. He mentioned that the data emancipates clinicians on therapies for metastatic colorectal cancer. The data helps in advancing cancer research and enhancing the healthspan and lifespan of patients with metastatic colorectal cancer.IntraGen’s molecular diagnostics director, Yann Gaston-Mathé, pointed out that the study is a manifestation of his company’s commitment to developing precision medicine therapies. Besides posting an article on Oncotarget, IntraGen signed a licensing deal together with CEBRA Laboratories. The deal allows the two companies to collaborate in developing a test that can be used in measuring miR-31-3p expression.

About Oncotarget

With an impact factor of 5.168, Oncotarget has gained recognition in the field of medicine as an open access and weekly peer-reviewed journal. Its publications cover scientific and clinical research on oncology. Since its release in 2010, Andrei Gudkov and Mikhail Blagosklonny have been serving as the senior editors. Oncotarget’s publications are usually indexed and abstracted in Scopus, Index Medicus/ PubMed, Science Citation Index Expanded and BIOSIS Previews.

Leave a Reply

Your email address will not be published. Required fields are marked *